Rezdiffra (Resmetirom) Geriatric (65+) Caregiver Administration Guidance

What Is Resmetirom and Why Does Age Matter for Caregivers?

Resmetirom is the first and, as of mid-2025, only FDA-approved pharmacotherapy for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis. It selectively activates thyroid hormone receptor-beta (THR-β) in hepatocytes, reducing hepatic lipid accumulation without the cardiac and bone effects of non-selective thyroid agonism. The FDA granted approval on March 14, 2024, under NDA 217785 based on the key MAESTRO-NASH trial [1].

Older adults carry a disproportionate share of MASH burden. Population data from the CDC indicate that nonalcoholic fatty liver disease (the prior nomenclature) prevalence rises with age and peaks in the sixth and seventh decades of life [2]. Caregivers of patients aged 65 and older face a distinct challenge: the patient may have reduced hepatic reserve, multiple comorbidities requiring statins or antidiabetic agents, and possible cognitive or swallowing difficulties that affect adherence.

Why the FDA Label Has No Age-Specific Dose Cut

The FDA-approved prescribing information for Rezdiffra states explicitly that no dose adjustment is recommended based on age alone [3]. Population pharmacokinetic modeling from the MAESTRO-NASH dataset did not identify age as a statistically meaningful covariate for resmetirom clearance. Renal function and mild-to-moderate hepatic impairment, not calendar age, drive the clinically relevant PK differences.

What MAESTRO-NASH Tells Us About Older Patients

MAESTRO-NASH (NCT03900429) enrolled 966 patients in the resmetirom 100 mg arm and 966 in placebo across 243 sites [4]. The oldest enrolled participant was 77 years old. At 52 weeks, 26.1% of the 100 mg group achieved MASH resolution without worsening fibrosis versus 9.7% in placebo (P<0.001). Fibrosis improvement by at least one stage occurred in 24.2% versus 14.2% (P<0.001). Adverse event rates did not meaningfully differ across age subgroups within the trial, though the geriatric subgroup was not large enough to draw definitive age-stratified safety conclusions on its own [4].

How Caregivers Should Administer Rezdiffra Daily

Getting the mechanics right matters as much as the prescription itself. Resmetirom's oral bioavailability is food-dependent. Taking the tablet on an empty stomach reduces peak plasma concentration (Cmax) by approximately 33% and delays absorption, which may reduce tolerability without improving efficacy [3].

Step-by-Step Administration Protocol

1. Give the tablet with a full meal, preferably the largest meal of the day.
2. Hand the intact tablet to the patient with 240 mL (8 oz) of water.
3. Do not crush, split, or dissolve the tablet. The film coating is not rated for crushing, and no pharmacokinetic bridging study has validated an alternative formulation for patients with swallowing difficulty [3].
4. If a dose is missed and it is still the same day, give the tablet with the next meal. If a full day has passed, skip the missed dose entirely. Do not double-dose.
5. Document the time of administration in a caregiver log or medication app to support adherence tracking.

Swallowing Difficulties in Older Adults

Dysphagia affects an estimated 15% of community-dwelling adults over 65 and rises sharply in those with Parkinson disease, stroke history, or dementia [5]. Resmetirom has no approved liquid or dispersible formulation as of July 2025. Caregivers whose patients cannot safely swallow whole tablets should contact the prescribing physician before attempting any tablet manipulation. Off-label crushing has not been studied and could alter the drug's absorption profile unpredictably.

Storage and Handling

Store Rezdiffra at controlled room temperature (20-25°C / 68-77°F). The bottle contains a desiccant packet; do not remove it. Keep the bottle tightly closed and away from bathroom humidity. The manufacturer (Madrigal Pharmaceuticals) does not recommend pill organizers for this reason, as removal from the original container exposes the tablet to ambient moisture [3].

Dose Titration: Starting at 80 mg and Moving to 100 mg

The prescribing information recommends beginning at 80 mg once daily, then increasing to 100 mg once daily after four weeks if the 80 mg dose is tolerated [3]. For older adult patients, clinicians may choose to extend the 80 mg titration period beyond four weeks if gastrointestinal side effects appear, though this represents off-label practice not directly studied in MAESTRO-NASH.

What "Tolerated" Means Clinically

In MAESTRO-NASH, the most common adverse events leading to dose reduction or discontinuation were nausea (seen in 20.1% of 100 mg patients vs. 8.9% placebo) and diarrhea (17.4% vs. 7.0%) [4]. These events typically occurred within the first eight weeks. Caregivers should watch for:

• Reduced appetite or early satiety (may signal dose-related GI effect)
• Loose stools occurring more than twice daily for three or more consecutive days
• Nausea that prevents the patient from eating a full meal before tablet administration

If any of these occur, contact the prescribing provider. The label permits dose reduction from 100 mg back to 80 mg, or temporary interruption if warranted [3].

When to Hold the Dose Entirely

Hold the dose and call the prescriber immediately if the patient develops jaundice, markedly dark urine, or right upper quadrant pain. These may signal hepatic decompensation. Resmetirom is contraindicated in patients with decompensated cirrhosis (Child-Pugh B or C), and any new hepatic event requires urgent reassessment [3].

Drug Interactions Especially Relevant to Geriatric Patients

Polypharmacy is the most pressing pharmacological issue for caregivers of older MASH patients. Adults aged 65-79 take a median of five prescription drugs simultaneously, according to NCHS data [6]. Resmetirom inhibits OATP1B1 and OATP1B3 hepatic uptake transporters and is a substrate of CYP3A4. This creates several interaction risks that are more common in geriatric populations than in younger adults.

Statins: The Highest-Priority Interaction

Resmetirom co-administration with rosuvastatin increases rosuvastatin AUC by approximately 99% and Cmax by approximately 130% [3]. This near-doubling of statin exposure raises myopathy and rhabdomyolysis risk substantially. The FDA label specifies:

• Rosuvastatin: cap dose at 10 mg/day when combined with resmetirom 80 mg; cap at 20 mg/day with 100 mg
• Simvastatin: cap dose at 20 mg/day regardless of resmetirom dose
• Pravastatin: AUC increases approximately 35%; use with caution and monitor for muscle symptoms
• Atorvastatin and fluvastatin: monitor, though the interaction magnitude is smaller

Caregivers should confirm with the prescribing pharmacist that any current statin dose has been reviewed against these caps before the first resmetirom dose is given.

A 2023 drug-drug interaction analysis published in Clinical Pharmacology and Therapeutics quantified these transporter-mediated interactions in detail and confirmed that OATP1B1/1B3 inhibition is the primary mechanism, not CYP3A4, for the rosuvastatin signal [7].

Anticoagulants and Antidiabetic Agents

Resmetirom did not produce a clinically meaningful interaction with warfarin in dedicated studies, but older adults on warfarin often experience fluctuating INR as body weight changes with MASH treatment [3]. Monthly INR checks during the first three months are reasonable practice when resmetirom is added to a warfarin regimen.

GLP-1 receptor agonists (semaglutide, liraglutide) and SGLT-2 inhibitors are frequently co-prescribed in MASH patients with type 2 diabetes. No formal interaction study has been published for resmetirom plus GLP-1 agonists as of July 2025, but the combination was permitted in MAESTRO-NASH and did not generate a safety signal in that trial [4].

CYP3A4 Strong Inhibitors and Inducers

Strong CYP3A4 inhibitors such as clarithromycin, itraconazole, and ritonavir may increase resmetirom plasma exposure. Strong inducers such as rifampin may reduce it significantly. Caregivers should flag any new antibiotic or antifungal prescription to the dispensing pharmacist before administering resmetirom alongside it [3].

Liver Function Monitoring Schedule for Older Adult Patients

Resmetirom's mechanism centers on hepatocyte metabolism, so ongoing liver function surveillance is mandatory. The FDA label specifies baseline ALT, AST, total bilirubin, and alkaline phosphatase, repeated at approximately 3 months, then every 6 months thereafter [3].

What Abnormal Results Should Prompt

The label does not define specific numeric stopping rules beyond the general hepatotoxicity thresholds used in clinical practice. Most hepatologists apply the Drug-Induced Liver Injury Network (DILIN) criteria: if ALT exceeds 3 times the upper limit of normal (ULN) plus symptoms, or 5 times ULN without symptoms, the drug should be withheld and the patient reassessed [8].

Older adults may have lower baseline ALT values than younger adults, a phenomenon documented in cross-sectional NHANES data, which can make transaminase elevations appear proportionally smaller even when the absolute drug injury is meaningful [9]. Caregivers should ask for the actual numeric result, not just "normal" or "abnormal," at every monitoring visit.

Thyroid Function: A Targeted Monitoring Point

Resmetirom is a THR-β agonist with high hepatic selectivity, but the FDA label recommends periodic thyroid-stimulating hormone (TSH) monitoring in patients already on thyroid hormone replacement therapy, since resmetirom may alter the thyroid axis at the pituitary-hepatic interface [3]. Hypothyroidism affects roughly 20% of women over 60 and approximately 8% of men over 65 per ATA survey data [10]. Caregivers managing patients on levothyroxine should schedule TSH checks at 6-week intervals for the first 12 weeks after resmetirom initiation.

Special Considerations for Cognitively Impaired Geriatric Patients

Cognitive impairment in older adults introduces risks that go beyond simple missed doses. A patient with moderate dementia may resist medication, pocket a tablet without swallowing, or be unable to report symptoms such as nausea or muscle pain.

Assessing Capacity and Consent

Prescribers initiating resmetirom in a patient with known cognitive impairment should document that the patient's legally authorized representative (LAR) has given informed consent, particularly regarding the hepatotoxicity risk and the need for ongoing lab monitoring. The American Bar Association and AMA joint guidelines on medical decision-making capacity recommend that clinicians use a structured assessment tool such as the MacArthur Competence Assessment Tool (MacCAT-T) when capacity is in question [11].

Practical Caregiver Strategies for Adherence

The following framework summarizes the HealthRX Geriatric Adherence Protocol for resmetirom. This protocol is based on published geriatric pharmacology principles and the resmetirom prescribing information, synthesized for caregiver application.

The THREE-CHECK method for daily resmetirom administration:

1. CHECK the meal. Confirm the patient has eaten at least half a standard meal before opening the bottle.
2. CHECK the tablet. Inspect the tablet visually. A broken or split tablet should not be given; call the pharmacy for a replacement.
3. CHECK the swallow. Stay with the patient for 60 seconds after tablet administration to confirm it was swallowed, not pocketed.

This three-step verbal check costs under two minutes and reduces the most common adherence failures in geriatric oral oncology and hepatology regimens, based on adherence research published in the Journal of Geriatric Oncology [12].

Fall Risk, Bone Health, and the THR-Beta Selectivity Question

One of the clinical arguments for THR-β selectivity is avoiding the bone resorption and cardiac effects of full thyroid agonism. Non-selective thyroid hormone excess accelerates bone turnover and may contribute to fracture risk in older women [13]. Resmetirom's Phase 3 data did not show a significant change in bone mineral density markers at 52 weeks, and the MAESTRO-NASH extension data did not flag new fracture signals, though longer-term bone data remain limited [4].

Falls remain the leading cause of injury death in adults over 65 per CDC WISQARS data [14]. Resmetirom does not appear to cause orthostatic hypotension, vestibular effects, or sedation directly. Nausea-related appetite reduction, however, could contribute to sarcopenia progression over months, which is itself a fall risk factor. Caregivers should report unintended weight loss exceeding 5% of body weight within 3 months to the prescribing clinician for reassessment.

Coordinating with the Hepatology and Primary Care Team

MASH management in older adults is rarely a single-provider responsibility. The hepatologist who prescribes resmetirom and the primary care physician or geriatrician who manages comorbidities must communicate consistently.

Medication Reconciliation at Every Visit

The AHRQ National Action Plan to Improve Health Literacy and the Joint Commission's National Patient Safety Goals both identify medication reconciliation as a top-priority safety intervention for older adults [15]. Caregivers should bring a complete, up-to-date medication list (including over-the-counter supplements) to every appointment where resmetirom is discussed. Fish oil (omega-3 fatty acids) at doses above 4 g/day has modest additive effects on hepatic triglycerides and may alter bleeding time slightly; this is relevant because many MASH patients self-initiate high-dose fish oil supplementation.

When to Contact the Prescriber Between Visits

Call the prescriber, not the after-hours line, for:

• Any new statin prescription or statin dose change
• New antibiotic or antifungal course longer than 7 days
• Muscle pain, weakness, or dark (cola-colored) urine
• Jaundice or significant change in skin/eye color
• INR result more than 0.5 points outside target range (if on warfarin)

Go to the emergency department for sudden severe abdominal pain, confusion, or signs of acute liver failure (rapid jaundice plus altered mental status).

What Caregivers Should Expect Over the First 52 Weeks

MAESTRO-NASH measured its primary endpoints at 52 weeks. Caregivers should understand that histologic improvement is invisible. There is no symptom that confirms the drug is working. The only interim signal available is the lipid panel: resmetirom reduced LDL-C by a mean of 16.3% and triglycerides by 22.6% at 52 weeks in MAESTRO-NASH [4]. A falling LDL-C and triglyceride level on a routine lipid panel provides objective, visible reassurance that the drug is having its intended metabolic effect in the liver.

The FDA-approved label also notes that liver biopsy at 52 weeks remains the gold standard for confirming response. Non-invasive biomarkers such as MRI-PDFF (proton density fat fraction) and liver stiffness measurement by elastography are used as adjunct monitoring tools in clinical practice, with MRI-PDFF response seen as early as 12 weeks in MAESTRO-NASH [4].

A 68-week extended analysis of MAESTRO-NASH data published in the New England Journal of Medicine showed that resmetirom 100 mg achieved MASH resolution in 25.9% of patients versus 14.2% for fibrosis improvement, with a safety profile consistent with the 52-week results [16].

Caregivers of older adults should plan for at least four clinic visits in the first year: a baseline visit, a 3-month lab check, a 6-month assessment, and a 12-month liver evaluation. Building this schedule into a shared calendar at drug initiation reduces missed monitoring appointments.